Robust enhancement of CD34⁺/CD43⁺/CD45⁺ HPCs in EBs derived from RUNX1a-transduced H9 cells. (A) Representative FACS analysis of CD34/CD45 or CD43/CD45 expression on day 9 EBs derived from vector or RUNX1a-transduced H9 cells. (B) Summary of FACS analysis of CD34/CD45 or CD43/CD45 expression on day 9 EBs derived from vector or RUNX1a-transduced H9 cells. Error bars represent SDs of 3 independent experiments. *P = .0002, **P = .0078. (C) Summary of FACS analysis of CD34/CD45 or CD43/CD45 expression on day 11 EB derived from vector or RUNX1a-transduced H9 cells. Error bars represent SDs of 3 independent experiments. *P = .04, **P = .03. (D) Summary of FACS analysis of CD34/CD45 or CD43/CD45 expression on day 13 EBs derived from vector or RUNX1a transduced H9 cells. Error bars represent SDs of 3 independent experiments. *P = .0003, **P = .001.